Please login to the form below

Not currently logged in

Digital intelligence blog

Pharma insight on digital marketing, social media, mobile apps, online video, websites and interactive healthcare tools

Boehringer launches ASCO blog to talk about lung cancer

Not Just One Disease set to cover a range of topics, including the patient journey

Boehringer launches ASCO blog to talk about lung cancerStepping up its social media efforts in time for this year's American Society of Clinical Oncology (ASCO) annual meeting Boehringer Ingelheim has launched a new lung cancer-focused blog.

The Not Just One Disease blog echoes Boehringer's ongoing messaging that patient diversity in lung cancer requires personalised treatment approaches.

But the blog won't be restricted to treatment topics and the company says the patient journey, researchers' perspective and the future of lung cancer care may all feature.

The blog was introduced by a post last week from Dr Mehdi Shahidi, who is associate therapeutic area head of solid tumour oncology within Boehringer's clinical development and medical affairs team.

He wrote: “At the core of Not Just One Disease is the simple fact that cancer, and especially lung cancer, is not just one disease. There are many distinct types and subtypes, and a tailored approach to treatment can improve patient outcomes.

“Over the five day meeting itself, we will provide overviews of current activities in the field of oncology and lung cancer, and also our social media #ASCO14 picks of the day.”

The blog will feature contributions from external experts and patient group representatives alongside posts by Boehringer personnel.

The ASCO meeting is one of the biggest events in the oncology world – more than 25,000 cancer specialists are expected to attend this year, but it poses a significant challenge for pharma companies wanting to stand out from their peers.

Boehringer and others in the industry already make substantial use of Twitter for pretty much every major congress as part of their communications efforts.

GlaxoSmithKline, for example, has its @GSK_Conferences account, which features tweets from GSK employees attending scientific conferences, and Merck & Co started tweeting about ASCO 2014 nearly two months ahead of the event.

Meanwhile, dedicated sections of web sites are often developed for specific congresses, such as within Boehringer's Newshome press portal or by Genentech for its own ASCO 2014 pages.

However, Boehringer's new disease and event-specific blog may well prove to be a smart way to cut through the noise at ASCO and could also mark a further step forward on road to greater virtual participation by pharma in the big scientific congresses.

The only slight anomaly that those journeying to Chicago for ASCO 2014 may notice is that Boehringer's new blog isn't aimed at them. “Because of country-specific regulations, the blog is only intended for those outside the US and UK”, a company disclaimer runs.

21st May 2014

From: Marketing



Subscribe to our email news alerts


Add my company
Havas Lynx Group

We are the Havas Lynx Group. Devoted to fresh thinking. Changing the way the world does healthcare communications for the...

Latest intelligence

Clinical Trials Investigator and Patient Engagement Planning: A Customer Story
New Playbook Alert: Virtual Patient Engagement
Millennials: the wellness generation
Looking at the results from a global healthcare research study focusing on the patients of the future...